Reduced serological response to COVID-19 vaccines in patients with IBD is further diminished by TNF inhibitor therapy; Early results of the VARIATION study (VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON)
| Autor: | Jayne Doherty, Neil O Morain, Roisin Stack, Parker Girod, Miriam Tosetto, Rosanna Inzitiari, Juliette Sheridan, Garret Cullen, Edel McDermott, Maire Buckley, Gareth Horgan, Hugh Mulcahy, Elizabeth J Ryan, David Daghfal, Peter Doran, Colm O Morain, Glen A Doherty |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Vaccines
COVID-19 Vaccines COVID-19 vaccination SARS-CoV-2 31 Biological sciences Vaccination Gastroenterology COVID-19 General Medicine anti-tumour necrosis antagonists Antibodies Viral Inflammatory Bowel Diseases digestive system diseases Inflammatory bowel disease Biological sciences Immunoglobulin G FOS: Biological sciences Humans Tumor Necrosis Factor Inhibitors |
| DOI: | 10.34961/researchrepository-ul.21525990.v1 |
| Popis: | Background and Aims Evidence suggests patients with inflammatory bowel disease [IBD] receiving TNF antagonists have attenuated response to vaccination against COVID-19. We sought to determine the impact of IBD and of various medications for treatment of IBD on antibody responses to vaccination against COVID-19. Methods Patients with IBD [n = 270] and healthy controls [HC, n = 116] were recruited prospectively, and quantitative antibody responses were assessed following COVID-19 vaccination. The impact of IBD and of medications for treatment of IBD on vaccine response rates was investigated. Results Of HC, 100% seroconverted following complete vaccination with two vaccine doses; 2% of patients with IBD failed to seroconvert. Median anti-spike protein [SP] immunoglobulin [Ig]G levels following complete vaccination in our IBD cohort was significantly lower than among HC [2613 AU/mL versus 6871 AU/mL, p ≤0.001]. A diagnosis of IBD was independently associated with lower anti-SP IgG levels [β coefficient -0.2, p = 0.001]. Use of mRNA vaccines was independently associated with higher anti-SP IgG levels [β coefficient 0.25, p ≤0.001]. Patients with IBD receiving TNF inhibitors had significantly lower anti-SP IgG levels [2445 AU/mL] than IBD patients not receiving TNF inhibitors [3868 AU/mL, p ≤0.001]. Patients with IBD not receiving TNF inhibitors still showed attenuated responses compared with HC [3868 AU/mL versus 8747 AU/mL, p = 0.001]. Conclusions Patients with IBD have attenuated serological responses to SARS-CoV-2 vaccination. Use of anti-TNF therapy negatively affects anti-SP IgG levels further. Patients who do not seroconvert following vaccination are a particularly vulnerable cohort. Impaired responses to vaccination in our study highlight the importance of booster vaccination programmes for patients with IBD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|